ZGNX (ZGNX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ZGNX (ZGNX) trades at $26.67 with AI Score 71/100 (Buy). Zogenix, Inc. , though currently carrying a $0M market cap, presents a compelling, albeit high-risk, investment opportunity within the biotechnology sector. Market cap: 0.
Last analyzed: Jan 21, 2026ZGNX Company Overview
Zogenix, Inc. aims to transform the lives of patients with rare diseases through Fintepla, a promising therapy despite the company's current unprofitability and lack of analyst coverage.
Investment Thesis
Zogenix presents a high-risk, high-reward investment opportunity. While the company's -278.4% net margin is concerning, potential growth catalysts include successful clinical trials and expanded indications for Fintepla. A strong competitive moat could be established if Fintepla becomes the standard of care for Dravet and Lennox-Gastaut syndromes.
Based on FMP financials and quantitative analysis
Competitors & Peers
Strengths
- High gross margin (94.1%) indicates strong pricing power
- Focus on rare diseases provides a niche market
- Current ratio of 3.63 indicates strong liquidity
Weaknesses
- Extremely negative operating and net margins (-259.6% and -278.4%)
- Lack of analyst coverage increases uncertainty
- Zero market cap suggests significant financial distress
Catalysts
- Upcoming: Phase III clinical trial results for Fintepla in Lennox-Gastaut syndrome (Q4 2026)
- Ongoing: Expansion of Fintepla's label to include other rare epileptic syndromes
Risks
- Valuation risk due to negative earnings and lack of market cap
- Operational risk associated with clinical trials and regulatory approvals
- Market risk associated with competition and pricing pressures
Growth Opportunities
- Expansion of Fintepla's label to include other rare epileptic syndromes (ongoing)
- Successful Phase III clinical trial results for Fintepla in Lennox-Gastaut syndrome (2026)
- Commercialization of MT1621 for other rare diseases (2027+)
- Partnerships with larger pharmaceutical companies for distribution and commercialization (ongoing)
Opportunities
- Potential for Fintepla to become the standard of care for Dravet and Lennox-Gastaut syndromes
- Expansion into new geographic markets
- Development of new therapies for other rare diseases
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and clinical trial failures
- Market risk associated with rare disease therapeutics
Competitive Advantages
- Potential for intellectual property protection on Fintepla
- Orphan drug designation provides market exclusivity
About ZGNX
Zogenix, Inc., founded in 2010 and headquartered in Emeryville, CA, is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. With a team of 327 employees, the company's primary focus is Fintepla, a low-dose fenfluramine treatment for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. Despite a $0M market cap, Zogenix aims to establish a strong market position by addressing unmet needs in rare epileptic syndromes. The company also has MT1621 in development, targeting other rare diseases. Zogenix operates primarily in the United States, seeking to expand its reach through clinical trials and potential partnerships.
What They Do
- Develop and commercialize therapies for rare diseases
- Conduct clinical trials to evaluate the safety and efficacy of their products
- Seek regulatory approvals from the FDA and other regulatory agencies
Business Model
- Sales of Fintepla
- Potential for licensing agreements with other pharmaceutical companies
- Government grants and funding for research and development
Key Customers
- Patients with Dravet syndrome
- Patients with Lennox-Gastaut syndrome
- Healthcare providers specializing in epilepsy treatment
Financials
Chart & Info
ZGNX (ZGNX) stock price: $26.67 (+0.41, +1.54%)
Latest News
-
Stocks That Hit 52-Week Lows On Friday
· Aug 20, 2021
-
Stocks That Hit 52-Week Lows On Thursday
· Feb 27, 2020
-
Stocks That Hit 52-Week Lows On Wednesday
· Feb 26, 2020
-
Stocks That Hit 52-Week Lows On Monday
· Feb 10, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ZGNX.
Price Targets
Wall Street price target analysis for ZGNX.
MoonshotScore
What does this score mean?
The MoonshotScore rates ZGNX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
What Investors Ask About ZGNX (ZGNX)
What does ZGNX do?
Zogenix, Inc. is a biopharmaceutical company that develops and commercializes therapies for rare diseases, with a primary focus on neurological disorders. Their lead product, Fintepla, is approved for the treatment of seizures associated with Dravet syndrome and is being investigated for other indications.
Who are ZGNX's main competitors?
Zogenix's main competitors include Albireo Pharma, Inc. (ALBO), Ambrx Biopharma Inc. (AMAM), CinCor Pharma, Inc. (CINC), CTI BioPharma Corp. (CTIC), and EQRx, Inc. (EQRX). These companies compete in various areas of the pharmaceutical industry, including rare diseases, biologics, and cardiovascular diseases.
What is ZGNX's competitive advantage?
Zogenix's competitive advantage lies in its orphan drug designation and patent protection for Fintepla, providing market exclusivity and a barrier to entry for competitors in the Dravet syndrome treatment market. The company's high gross margin also indicates a strong pricing power.
How does ZGNX make money?
Zogenix generates revenue primarily through the sale of Fintepla for the treatment of Dravet syndrome. Future revenue streams are expected from potential approvals and sales of Fintepla for other indications, as well as potential out-licensing or partnership agreements for other drug candidates.
Is ZGNX profitable?
No, Zogenix is currently not profitable. The company's operating margin is -259.6% and its net margin is -278.4%, indicating significant losses due to high R&D and commercialization expenses.
What are the key factors to evaluate for ZGNX?
ZGNX (ZGNX) currently holds an AI score of 71/100, indicating high score. With a beta of 0.90, ZGNX is roughly in line with the broader market. The company maintains a 94% gross margin. Key strength: High gross margin (94.1%) indicates strong pricing power. Primary risk to monitor: Valuation risk due to negative earnings and lack of market cap. This is not financial advice.
How frequently does ZGNX data refresh on this page?
ZGNX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ZGNX's recent stock price performance?
Recent price movement in ZGNX (ZGNX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. With a beta of 0.90, ZGNX tends to move roughly in line with the broader market. Notable catalyst: High gross margin (94.1%) indicates strong pricing power. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of October 2023.